Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19IL2 plus rituximab in relapsed or refractory DLBCL
2014-001949-25Phase 2Terminated
- Sponsor
- Philogen
- Start
- Jul 2014
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darleukin in diffuse large B-cell lymphoma (DLBCL), sponsored by Philogen. Primary endpoints: Complete response rate (Phase II primary), Maximum tolerated dose and 2 more. Started Jul 2014; status: terminated.
02
Drugs
darleukin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2014-001949-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001949-25.